Home >> Events >> Dermatology Innovation Leadership Think Tank

Events

Dermatology Innovation Leadership Think Tank

May 19, 2021

Event Details

CAR-T Cells as a Therapy for γδ T-cell Cancers

Join us at the Dermatology Innovation Leadership Think Tank meeting featuring Christoph Ellebrecht, MD and Aimee Payne, MD, PhD, of University of Pennsylvania, as they discuss Chimeric antigen receptor (CAR) T cells as a precision curative therapy for gamma-delta T cell cancers.

The University of Pennsylvania’s successes in treating cancer with CAR T cell therapy represent two decades of investment in the people and infrastructure to advance these novel cellular immunotherapies to clinical trials. Clinician-scientists of all disciplines and in every career stage are now empowered to harness the immune system to treat more cancers, as well as other immune diseases.

Webinar Takeaways:

• Understand how chimeric antigen receptor technology harnesses the immune system’s power to induce lasting remissions of previously refractory B cell leukemias and lymphomas.
• See how breakthrough discoveries in B cell-mediated cancers have led to innovative approaches for B cell-mediated autoimmune diseases that may offer similar potential for lasting remission.
• Learn how novel CAR technologies can provide opportunity to impactfully treat and potentially cure a breadth of gamma-delta T cell leukemias and lymphomas.

Who Should Attend?

• Physicians
• Scientists
• Investors
• Product Development Organizations
• Government Officials & Regulators
• Patient Advocacy Organizations

About the Presenters:

Penn Medicine’s Aimee Payne, MD, PhD, continues to re-define this field. Dr. Payne is Professor of Dermatology and Director of the Penn Clinical Autoimmunity Center of Excellence at the University of Pennsylvania. She is also co-founder and co-chair of the Scientific Advisory Board at Cabaletta Bio (NASDAQ:CABA), focused on targeted cellular immunotherapies of B cell-mediated diseases. Her group invented a precision cellular immunotherapy for autoimmunity known as DSG3-CAART, which is being evaluated in a first-in-human clinical trial that launched in 2020.

Christoph Ellebrecht, MD, rising Clinical Instructor of Dermatology and co-inventor of DSG3-CAART, is now expanding CAR-T technology to create one of the few programs targeting gamma-delta T cell cancers, a rapidly lethal group of cancers notoriously refractory to current chemotherapeutic approaches. Targeting the gamma-delta T cell receptor with CAR T cells offers a potentially curative therapy for this devastating group of cancers with high unmet need for effective treatments.